Pressure BioSciences (Pressure BioSciences) Cash, Cash Equivalents, Marketable Securities : $0.01 Mil (As of Sep. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Pressure BioSciences Cash, Cash Equivalents, Marketable Securities?

Pressure BioSciences's quarterly cash, cash equivalents, marketable securities declined from Mar. 2023 ($0.24 Mil) to Jun. 2023 ($0.03 Mil) but then stayed the same from Jun. 2023 ($0.03 Mil) to Sep. 2023 ($0.01 Mil).

Pressure BioSciences's annual cash, cash equivalents, marketable securities increased from Dec. 2020 ($0.02 Mil) to Dec. 2021 ($0.13 Mil) but then declined from Dec. 2021 ($0.13 Mil) to Dec. 2022 ($0.00 Mil).

Pressure BioSciences Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Pressure BioSciences's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pressure BioSciences Cash, Cash Equivalents, Marketable Securities Chart

Pressure BioSciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

0.10

0.03

0.02

0.13

Pressure BioSciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															0.23	-	0.24	0.03	0.01

Pressure BioSciences Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Pressure BioSciences (OTCPK:PBIO) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Pressure BioSciences Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Pressure BioSciences's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Pressure BioSciences (Pressure BioSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pressure BioSciences Inc (OTCPK:PBIO) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

14 Norfolk Avenue, South Easton, MA, USA, 02375

Website

https://www.pressurebiosciences.com

Pressure BioSciences Inc is engaged in the healthcare division. The firm is a leader in the development & sale of innovative, enabling, pressure-based platform solutions for the worldwide life sciences industry. The company has developed and patented a technology platform that can control the sample preparation process. This process, called pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels. The company is also the distributor of the Constant Systems (CS) cell disruption equipment, parts, and consumables. Its products include Barocyclers, External Pressure Calibration Device Kits, MicroTubes, HUB High-Pressure Generators, and Accessories.

Executives

Daniel Joseph Shea	officer: Senior Vice President & CFO	2 MINUTEMAN ROAD, MEDFIELD MA 02052
Bradford Addison Young	officer: Chief Commercial Officer	513 LITTLE JOHN HILL, ANNAPOLIS MD 21405
Richard T Schumacher	director, officer: Chief Executive Officer	375 WEST STREET, WEST BRIDGEWATER MA 02379
Nathan Lawrence	other: VP Sales and Marketing	321 MANLEY STREET, WEST BRIDGEWATER MA 02379
Richard Thomley	officer: Chief Financial Officer	C/O PRESSURE BIOSCIENCES, INC., 14 NORFOLK AVE., SOUTH EASTON MA 02375
Kevin Pollack	director	150 RAINVILLE ROAD, TARPON SPRINGS FL 34689
Michael S Urdea	director	100 BUNCE MEADOWS DRIVE, ALAMO CA 94507
Alexander V Lazarev	officer: VP of REsearch and Development	18 WINCHESTER DRIVE, LEXINGTON MA 02420
Edmund Y Ting	officer: Senior VP of Engineering	23642 123RD PLACE SOUTHEAST, KENT WA 48031
Vito J Mangiardi	director	12 POINT GALLINAS ROAD, SAN RAFAEL CA 94903
Jeffrey N Peterson	director	1031 SHORELINE DRIVE, SAN MATEO CA 94404
Mir Conrad F	officer: CFO	19 BRIER LANE, CLIFTON NJ 07012
Clayton A Struve	10 percent owner	175 W JACKSON BLVD, SUITE 440, CHICAGO IL 60604
Css Llc/il	other: (a)	175 WEST JACKSON BLVD, SUITE 440, CHICAGO IL 60604
R Wayne Fritzsche	director	835 GREENS PARKWAY, SUITE 150, HOUSTON TX 77067